Aditxt Earlier Announced Its Psoriasis Clinical Program Will Now Be Slated For 2022 Instead Of Dec. 2021
Psoriasis First-in-Human (Phase I/IIa) program is slated for 2022
Type 1 Diabetes and Skin Allografting are planned to enter clinical trials in 2022
Pre-clinical investigational work has started in Multiple
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers
Eyegate Pharmaceuticals (NASDAQ:EYEG) stock increased by 25.64% to $3.92 during Monday's after-market session. The company's market cap stands at $27.8 million.
Aditxt’s COVID-19 Test To Include Specific Antibodies To Detect Individual Immune Response; Shares Rise
Aditxt Inc (NASDAQ:ADTX) has announced enhancements to its AditxtScore for COVID-19 to include a high-sensitivity neutralizing antibody diagnostic. The multi-dimensional immune…
Aditxt Launches High-Sensitivity Neutralizing Antibody Test to Detect Individual Immune Response to COVID-19
Aditxt, Inc. (“Aditxt”) (NASDAQ:ADTX), a biotech innovation company with a mission to improve the health of the immune system, today announced enhancements to its AditxtScore™ for COVID-19. A